Central Oncology Review
Specialized Institutional Review Board (IRB) Services for an Evolving Regulatory Landscape
Aligned with the needs of the growing and increasingly complex field of oncology, Advarra’s Central Oncology Review (COR) provides the robust human subject protections review cancer research institutions expect.
IRB Experience in Oncology
- Antibody-drug conjugates
- Bladder/urinary tract cancer
- Blood and lymph cancers
- Breast cancer
- Cancer diagnostics
- Cervical cancer
- Colon/colorectal cancer
- Endometrial cancer
- Gastric cancer
- Gene therapy
- Head and neck cancer
- Immunotherapy (such as CAR-T cell therapy)
- Liver cancer
- Lung cancer
- Ovarian cancer
- Pancreatic cancer
- Palliative care management
- Precision medicine (such as basket, umbrella, and targeted therapy trials)
- Prostate cancer
- Renal cancer
- Skin cancer
Can Advarra serve as the single IRB for federally funded research?
Yes, Advarra oversees many single site and multisite studies supported by the NIH, NCI, DoD, and other agencies.
Can Advarra serve as the single IRB for oncology network research?
Yes, Advarra has experience supporting therapeutically specialized research networks. For more information, see IRB Services for Institutions, Health Systems, and Research Consortia.
How do I defer IRB oversight to Advarra?
We’ll work with your organization to establish a deferral agreement. Then we will coordinate with institutional leadership to accommodate local requirements and train teams as needed. Contact our team to get started.
Streamline your research operations with OnCore, the preferred enterprise research CTMS of NCI-designated cancer centers
Advancing Equality and Inclusion in Oncology Clinical Trials
According to the Association for Clinical Oncology, individuals who identify as African American or Black make up 13.4% of the...
The recently passed Clinical Treatment Act and Henrietta Lacks Enhancing Cancer Research Act aims to increase diversity in oncology clinical trials by reducing barriers to participation for under-represented populations. This blog overviews how these new legislations can remove barriers to participate in oncology clinical trials.
Q&A – The New Urgency of Clinical Trials: How Oncology Leads the Evolution
In Advarra’s recent virtual symposium, experts from industry and academia met to discuss how oncology research has influenced agility in clinical trial design, particularly during the COVID-19 pandemic. Panelists talked ...
How has the COVID-19 pandemic changed oncology research--and research in general? Read more for the follow-up blog to our recent symposium:
How Oncology Research Is Advancing Better Research
The COVID-19 pandemic has challenged every aspect of the clinical research industry. This new urgency has affirmed certain clinical trial innovations originally pioneered in the oncology space.
Innovations in oncology have sparked advancements in the clinical trial industry and empowered COVID-19 research. Read more: